[结直肠癌病例中CA-50的临床评估]
[Clinical evaluation of CA-50 in cases with colorectal cancer].
作者信息
Nishida O, Ohmori K, Shiroto H, Sawaguchi Y, Satoh N, Nakajima Y, Manabe K, Kondoh Y, Sano F, Uchino J
机构信息
Dept. of Surgery, Hokkaido Univ. School of Med.
出版信息
Gan No Rinsho. 1989 Apr;35(5):605-8.
Serum CA-50 has been evaluated in 67 healthy donors and in 46 patients with a colorectal cancer by an enzyme immunoassay (EIA Kit, Mitsui pharmaceuticals, Inc.). The mean value of the healthy donors (n = 67) was 10.6 +/- 6.1 U/ml and for patients with a colorectal cancer 31.7 +/- 55.2 U/ml. Both in healthy donors and in patients, the mean value was found to be higher in females than males. The overall sensitivity in the colorectal cancer patients was 26.1 percent, the percentages for those in stage I, 20, II, 9.1, III, 40, IV, 20, and V, 50% respectively. In a correlation between serum CA-50 and CA 19-9, the correlation coefficient was 0.82 (p less than 0.01), and in between CA-50 and CEA, 0.51 (p less than 0.01). Thus a combination assay among CA-50, CA 19-9, and CEA has proved to be of significant value in cases of a colorectal cancer.
采用酶免疫分析法（三井制药公司的酶免疫分析试剂盒）对67名健康供者和46名结直肠癌患者的血清CA - 50进行了评估。健康供者（n = 67）的平均值为10.6±6.1 U/ml，结直肠癌患者的平均值为31.7±55.2 U/ml。在健康供者和患者中，均发现女性的平均值高于男性。结直肠癌患者的总体敏感性为26.1%，I期患者为20%，II期为9.1%，III期为40%，IV期为20%，V期为50%。血清CA - 50与CA 19 - 9之间的相关系数为0.82（p < 0.01），CA - 50与癌胚抗原（CEA）之间的相关系数为0.51（p < 0.01）。因此，CA - 50、CA 19 - 9和CEA联合检测在结直肠癌病例中已被证明具有重要价值。
Zotero 插件